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a  b  s  t  r  a  c  t
NuThraxTM (Anthrax  Vaccine  Adsorbed  with  CPG  7909  Adjuvant)  (AV7909)  is  in development.  Samples
obtained  in a phase  Ib clinical  trial were  tested  to conﬁrm  biomarkers  of  innate  immunity  and  evaluate
effects  of CPG  7909  (PF-03512676)  on adaptive  immunity.  Subjects  received  two  intramuscular  doses
of  commercial  BioThrax® (Anthrax  Vaccine  Adsorbed,  AVA),  or two  intramuscular  doses  of one  of four
formulations  of  AV7909.  IP-10,  IL-6, and  C-reactive  protein  (CRP)  levels  were  elevated  24–48 h  after
administration  of  AV7909  formulations,  returning  to baseline  by  Day  7. AVA  (no CPG  7909)  resulted  in
elevated  IL-6  and  CRP,  but not  IP-10.  Another  marker  of  CpG,  transiently  decreased  absolute  lymphocyte
counts  (ALCs),  correlated  with  transiently  increased  IP-10.  Cellular  recall  responses  to anthrax  protective
antigen  (PA)  or PA  peptides  were  assessed  by  IFN-  ELISpot  assay  performed  on cryopreserved  PBMCs
obtained  from  subjects  prior to immunization  and 7 days  following  the  second  immunization  (study
day  21). One-half  of  subjects  that received  AV7909  with  low-dose  (0.25  mg/dose)  CPG  7909  possessed
positive  Day 21 T cell  responses  to PA.  In contrast,  positive  T cell  responses  occurred  at  an  11%  average
rate  (1/9)  for  AVA-treated  subjects.  Differences  in  cellular  responses  due  to  dose  level of CPG 7909  were
not associated  with  differences  in  humoral  anti-PA  IgG  responses,  which  were  elevated  for  recipients  of
AV7909  compared  to  recipients  of  AVA.  Serum  markers  at 24  or  48  h  (i.e. % ALC  decrease,  or  increase  in
IL-6,  IP-10,  or  CRP)  correlated  with  the  humoral  (antibody)  responses  1 month  later,  but did  not  correlate
with cellular  ELISpot  responses.  In summary,  biomarkers  of  early  responses  to  CPG  7909  were conﬁrmed,
and  adding  a CpG  adjuvant  to a vaccine  administered  twice  resulted  in  increased  T cell  effects  relative  to
vaccine  alone.  Changes  in  early  biomarkers  correlated  with  subsequent  adaptive  humoral  immunity  but
not cellular  immunity.. Introduction
NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 adju-
ant) (AV7909) is a post-exposure prophylaxis (PEP) anthrax
accine candidate being developed to accelerate the immune
esponse and minimize the number of injections needed to confer
rotective immunity. AV7909 contains AVA bulk drug substance
s a source of Protective Antigen (PA) immunogen, aluminum
ydroxide, and the toll-like receptor 9 (TLR9) agonist CPG 7909
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(PF-03512676). Administration of AV7909 stimulates the immune
system to produce toxin-neutralizing antibodies directed to PA,
a component of anthrax toxins [1]. Human CpG biomarkers can
become the basis for in vitro assays that are useful during vaccine
development.
Human serum biomarkers affected by CpG adjuvants include
increased IP-10 and IL-6 [2], IL-12, MCP-1 and IFN- [3] as
well as enhanced antibody responses [1,4,5]. Also reported were
transiently decreased absolute lymphocyte counts (ALCs) and C-
reactive Protein (CRP) after subcutaneous (SC) administration
[3,6,19], in vitro interferon-gamma (IFN-) production by periph-
eral blood mononuclear cells (PBMC) obtained after in vivo CpG
treatment [4], increased T cell expansion [7], increased circulating
T cells and NK cells after intra-venous (IV) administration [6] and
increased CD8+ T cells. In vitro responses to CpG2006 or CPG 7909
included enhanced IL-10, IL-6, IFN- [8], IL-8 [9] by human plas-
macytoid dendritic cells, as well as increased PBMC production of
IL-6, IL-10, IFN-, IFN-, and IP-10 [9,10] and enhanced CD8+ T cells
developed from PBMC [9,11].
reserved.
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Table 1
Vaccine formulations, study design and number of donor samples.
Study arm AV7909 formulation Active ingredients and vaccine amounts Subjects per arm (N)a ELISpot subjects per
armb (N)
ELISA subject samples
per arm (N)
1 None AVA 0.5 mL  (BioThrax®) 17 15 14–15c
2 1, or F1 AVA 0.5 mL  + CPG 7909 0.5 mg  18 15 17
3  2, or F2 AVA 0.5 mL  + CPG 7909 0.25 mg 17 15 16
4  3, or F3 AVA 0.25 mL  + CPG 7909 0.5 mg 19 18 17–18d
5 4, or F4 AVA 0.25 mL  + CPG 7909 0.25 mg 18 16 18
6  None None 15 14 14–15e
a The group sizes (n = 15–19) for samples used for determinations of early biomarkers were the same as number of enrolled subjects reported in [14], with the exception
that  a subject in Arm 1 was included for early biomarker determinations that did not continue in the study beyond Day 7.
b ELISpot testing was performed using PBMC from blood collected on Days 0 and 21 if meeting criteria that Subject’s Day 0 and D21 samples passed Trypan blue viability.
p
d
r
t
n
i
v
i
a
1
s
A
s
a
w
c
p
I
a
2
2
D
p
a
p
i
t
o
c
T
A
[c One Subject’s ELISA samples were not available on Day 70.
d One Subject’s ELISA samples were not available on Day 28.
e One Subject’s ELISA samples were not available on Day 42.
The contributions of cell-mediated immune responses to the
roduction of anthrax toxin-neutralizing antibodies remain to be
eﬁned. Although human T cell epitopes within the PA molecule,
estricted by 2 different HLA allotypes were identiﬁed using
etramer guided epitope mapping [12,13], neither these epitopes
or other peptides have been tested previously for capacity to
nduce T cell recall responses in PBMC from recipients of anthrax
accines.
As exploratory endpoints in the clinical trial designed to
nvestigate the safety and immunogenicity of intramuscular (IM)
dministration of AVA formulated with CPG 7909 adjuvant [14], IP-
0, IL-6, C-reactive protein (CRP), and ALC were evaluated in blood
amples obtained from human AV7909 recipients and compared to
VA recipients. To investigate T cell responses to PA protein, PBMC
amples from immunized subjects were re-stimulated in vitro with
 mixture of predicted HLA class II restricted PA peptide epitopes or
ith recombinant PA (rPA) and were visualized as IFN--producing
ells using an enzyme-linked immunospot (ELISpot) technique. The
otential correlations of these markers with subsequent serum
gG anti-PA responses (present manuscript), and toxin neutralizing
ntibody responses [14] were evaluated.
. Materials and methods
.1. Study design
A randomized double-blinded clinical study (“EBS.AVA.201/
MID 10-0013”; Trial # NCT01263691) [14] was conducted in com-
liance with the Declaration of Helsinki and ICH guidelines, under
n investigational new drug (IND) application. After the nature and
ossible consequences of the study were fully explained to subjects,
nformed consent was obtained. Four formulations of AV7909 con-
ained either 0.5 mL  or 0.25 mL  of AVA with either 0.25 or 0.5 mg
f CPG 7909. A full dose of AVA (0.5 mL)  was administered as a
omparator vaccine. Saline served as placebo vaccine. Table 1 lists
able 2
mino acid sequences of predicted HLA class II-restricted PA-derived peptide epitopes an
Peptide number Amino acid sequence 
1a LGYYFSDLNFQAPMVVTSS 
2  TVDVKNKRTFLSPWI 
3a SSTVAIDHSLSLAGE 
4a NANIRYVNTGTAPIYNV 
5  LDKIKLNAKMNILIR 
6a KMNILIRDKRFHYDR 
7  RYDMLNISSLRQDGK 
8  DKDIRKILSGYIVEI 
9a KLPLYISNPNYKVNV 
10  ISSLRQDGKTFIDFK 
a This sequence, predicted independently with the in silico programs, is identical to or
13], detected using tetramer staining.vaccine formulations, doses, and sample sizes for each of 6 treat-
ment groups, and an explanation if the sample size differed from the
number of subjects who  completed the study [14]. An equivalent
number of male and female subjects were included across the arms
of the study; demographic information is available in the Hopkins
et al. paper [14].
Samples (101) were collected during subject visits at 0, 1, 2, and
7 days after the ﬁrst dose of vaccine to evaluate CRP, IP-10, and IL-6
levels, as well as changes in ALC. Both CRP, measured with high-
sensitivity nephelometry assay (Roche Diagnostics, Indianapolis,
IN) and ALC (derived from the CBC) were performed commercially
(ACM Global Laboratory, Rochester, NY). IP-10 and IL-6 ELISAs are
described below. Cellular responses were evaluated 7 days after the
second administration of vaccine. Antibody responses were eval-
uated to determine anti-PA IgG levels in serum samples collected
on Day 0, 14, 28, 42, and 70 (this paper) and toxin-neutralizing
antibody (TNA) levels [14].
2.2. IFN- enzyme-linked Immunospot assay (ELISpot)
Prior to the ﬁrst vaccine dose, and 7 days after the second
vaccine dose (study day 21), PBMC were isolated from venous
blood samples, and stored in liquid nitrogen vapors at SeraCare
Life Sciences (Gaithersburg, MD). For ELISpot controls: stimulants
were phytohaemmaglutinin (PHA; mitogen, control for viability,
Sigma, St Louis, MO)  and CEF I peptide pool (Cellular Technol-
ogy Ltd; Shaker Heights, OH) representing HLA Class I-restricted
peptides from cytomegalovirus, Epstein Bar virus and inﬂuenza
virus (CEF). Recall antigens were rPA (Emergent BioSolutions,
Gaithersburg, MD)  or a pool of 10 PA-derived peptides (PAps)
(ProImmune, Oxford, UK). Sequences for PAps were selected on the
basis of (1) high binding scores calculated by SYFPEITHI [15] and
PROPRED [16] in silico programs, (2) predicted binding by mul-
tiple HLA Class II types, (3) low hydrophobicity and (4) absence
of cytotoxicity to naïve PBMC. Stimulation by PAp mixture was
d the restricting HLA haplotypes.
Predicted HLA class II preferences
DRB1*01, DRB1*04, DRB1*11, DRB1*15
DRB1*04, DRB1*08, DRB1*11, DRB1*13
DRB1*03, DRB1*15
DRB1*01, DRB1*03, DRB1*04, DRB1*07, DRB1*08, DRB1*11, DRB1*13
DRB1*03, DRB1*11, DRB1*13
DRB1*08, DRB1*11, DRB1*13
DRB1*04, DRB1*11, DRB1*13
DRB1*04, DRB1*07, DRB1*15
DRB1*01, DRB1*03, DRB1*07, DRB1*11, DRB1*13
DRB1*03, DRB1*11
 has signiﬁcant sequence homology with published class-II restricted PA peptides
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V7909 F2 (AVA 0.5 ml  + CpG 0.25 ml); AV7909 F3 (AVA 0.25 ml  + CpG 0.5 ml); AV
tatistical differences (p < 0.05 following post hoc analysis using MANOVA) of IP-10 
erformed with a ﬁnal concentration of 10 g/mL of each peptide.
Ap amino acid sequences and restricting HLA haplotypes are listed
n Table 2.
PBMC were thawed in serum-free medium, re-suspended to a
ensity of 1–2 × 106 viable cells/mL, rested overnight at 37 ◦C, 5%
O2, recounted and adjusted to target viable cell densities. For IFN-
LISpot, stimulants and antigens (50 L) were delivered to 96-well
lates (SeraCare LifeSciences), followed by PBMC (50 L per well,
00,000 cells; or 100,000 cells for PHA wells). Final volume per
ell was 100 L. PHA was tested in duplicate wells and all oth-
rs in triplicate. PBMC from a single-donor (SeraCare Cat. # 1074)
hich responded to CEF I stimulation with IFN- production, were
ncluded in every plate to assess experimental variability. After
0–48 h of incubation, IFN- spot forming cells (SFC) were enu-
erated using an ELISpot plate reader (Cellular Technology Ltd.). Apeciﬁcity rate of 100% and a sensitivity rate of 79% were achieved
sing SFC counts at cut-off levels of ≥200 for PHA- and ≥15 for
EF I-stimulated cells. Speciﬁcity and sensitivity rates were lower
f fewer SFC for PHA and CEF I were analyzed.groups of the EBS.AVA.201 study. Vaccines: AV7909 F1 (AVA 0.5 ml  + CpG 0.5 ml);
 F4 (AVA 0.25 ml  + CpG 0.25 ml); AVA = BioThrax (0.5 mL); placebo (0.5 ml saline).
m were identiﬁed between AV7909 (formulations 1–4) relative to AVA or placebo.
2.3. Cytokine ELISA
Serum samples obtained at study sites were stored at −70 ◦C
until assayed. QuantikineTM ELISA kits (R&D Systems, Minneapolis,
MN)  for IL-6 (HS600B) and IP-10 (DIP100) were obtained from
single production lots. Positive controls were purchased and
quantiﬁed and included on each plate. Log-transformed values of
test samples were analyzed using linear regression and compared
to a standard curve. Samples for a single subject obtained at several
time-points were tested on the same ELISA plate.
2.4. Anti-PA IgG ELISA
ELISA plates (Nunc Maxisorp) were coated using rPA (1 g/mL)
for 2–5 days at 4 ◦C. Test samples diluted into phosphate buffered
saline (PBS) that contained 5% milk powder (DIFCO Laboratories,
Detroit, MI)  and 0.05% Tween 20 (PBSMT) were added and incu-
bated for 1 hour at 37 ◦C. Plates were washed using PBS with
0.5% Tween-20 (PBST), HRP anti-human IgG (Kirkegaard and Perry
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aboratories (KPL); Gaithersburg, MD)  added, and incubated for
 hour at 37 ◦C, washed using PBST and developed using ABTS col-
rigenic substrate (KPL). Data were analyzed using a 4-parameter
ogistic ﬁt, compared to Emergent’s reference antiserum that was
ualiﬁed at Battelle Eastern Science and Technology (lot # BEST
S.EBS.001).
.5. Statistical analyses
For ELISpot analysis, PBMC samples were available for 94 sub-
ects. ELISpot subjects were excluded that failed positive control
timulant cut-offs deﬁned as a minimum of 15 CEF I SFC or
00 PHA SFC. Empirical deﬁnition of an antigen-speciﬁc posi-
ive response (for subjects not excluded per above criteria) was
et at a minimum of 9 SFC in wells with rPA (or PAp) and at
east two-fold higher than background (SFC counts in wells with
edium alone). Scharp analysis [17] calculated the positive respon-
er rates to PAp and rPA, using triplicate SFC counts entered online
ttp://www.scharp.org/zoe/runDFR/. Scharp analyses are based on
ig. 2. Average of the subject’s individual IL-6 Cytokine responses (pg/mL) among all group
2  (AVA 0.5 ml  + CpG 0.25 ml); AV7909 F3 (AVA 0.25 ml  + CpG 0.5 ml); AV7909 F4 (AVA 0.
L-6  in serum differed between AV7909 (formulations 1–4) or AVA relative to placebo p
rom  that in AV7909 formulations 1–4 (p > 0.05).2 (2014) 6847–6854
distribution-free random sampling (DFR) to increase the strength of
the analysis. Those samples having ELISpot data for medium alone
(negative control), PAp and rPA were included in the analysis for
the Scharp analysis requirement of at least three treatments, tested
in three or more replicates.
The Suissa-Shuster Exact test [18] was  performed to compare
the response rate due to different dose levels of AVA and AV7909.
IP-10 and IL-6 results were analyzed by a General Linear model
with post hoc analysis using MANOVA. The Spearman’s rank cor-
relation coefﬁcient method was used to measure associations
between biomarkers.
3. Results
3.1. IP-10, IL-6, ALC and CRP levelsThe time course of IP-10 and IL-6 serum levels in AV7909 recip-
ients increased over 24–48 h in a manner consistent with that
previously reported [19] with peak serum levels observed at 24 h,
s of the EBS.AVA.201 study. Vaccines: AV7909 F1 (AVA 0.5 ml  + CpG 0.5 ml); AV7909
25 ml  + CpG 0.25 ml); AVA = BioThrax (0.5 mL); placebo (0.5 ml saline). Statistically,
 < 0.05 following post hoc analysis using MANOVA. But AVA IL-6 was not different
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Fig. 3. Associations between immune activities of CpG. (A1) Increased IP-10 (pg/mL, baseline-subtracted) at 24 h by Arm was correlated with decreases in the percentage of
circulating lymphocytes (Spearman correlation, r = −0.76, p < 0.0001). (A2) IL-6 levels (pg/mL, baseline-subtracted) at 24 h by Arm versus reactogenicity marker, CRP (mg/L) at
48  h (Spearman correlation, r = 0.6, p < 0.0001). AVA = BioThrax. (B) Spearman Rank correlations (r) of pairwise comparisons for the different biomarker combinations. “IFN-
SFC” is the PBMC response to rPA antigen on Day 21 measured in ELISpot. “TNA (NF50)” was determined in the companion study [14] with sera samples obtained from the
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raph  relate the r threshold equivalent to this alpha level.
s shown in Figs. 1 and 2. Post hoc analysis (by group) for IP-10,
evealed that all AV7909 groups were statistically different from
VA and saline (placebo) groups. Post hoc analysis for IL-6 (by
roup) revealed a trend toward higher IL-6 for AV7909 than AVA
hat was not statistically different, yet both were statistically dif-
erent from the saline group (Fig. 2). Like IP-10, IL-6 serum levels
eturned to pre-immunization levels by day 7.
All formulations of AV7909 induced greater changes in ALC and
lood CRP levels than either AVA or saline. The X-axis of Fig. 3A1
nd A2 illustrates the overall changes in these markers, with the
esponses separated for each treatment group. Also shown in Fig. 3A
re IP-10 and IL-6 data at 24 h, a time point of peak elevation, and
elationship to ALC or CRP. As expected, there was a correlation
etween the observed decrease in ALC and the increase in IP-10
evels 24 h after immunization (r = −0.76) (Fig. 3A). Increased CRP
t 48 h was associated with increased IL-6 at 24 h (r = 0.59) (Fig. 3A).
dditionally, there was a signiﬁcant association of Day 28 TNA NF50
alues reported by Hopkins et al. [14] with IP-10, IL-6, ALC, and
RP. In addition, Day 28 IgG antibody levels directed against PAwhich occurred at Day 28 or 35. Graph depicts the correlation statistics adjacent to
f r = 0; for statistical signiﬁcance alpha is set to p < 0.0010. Dotted vertical lines on
(reported below) correlated signiﬁcantly with these early innate
biomarkers (Fig. 3B).
3.2. IFN- T cell Recall Responses to PAp and rPA
Fig. 4A presents the sequence of steps by which PBMC ELISpot
data in each of 6 treatment groups were analyzed for responder
rates. Using criteria to include only those PBMC pairs (day 0 and
day 21) having adequate positive responses to PHA or CEF-I, the
IFN- ELISpot responder rate to PAp and/or rPA averaged 11% (1/9)
in recipients of two  full (0.5 mL)  doses of AVA. In contrast, a signif-
icantly higher IFN- response rate was observed for the subjects
in treatment groups that received the lower amount of CPG 7909
(0.25 mg), resulting in 5/11 and 7/12 positive responders for For-
mulations 2 and 4, respectively compared to those that received a
higher amount of CPG 7909 (Suissa-Shuster, p = 0.03). There were
no responders in the placebo group.
Using the Suissa-Shuster unconditional test [18], the IFN-
responder rates of subjects immunized with AV7909 formulations
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Fig. 4. (A). Break down of viable PBMC samples included in human IFN- ELISpot analyses and further paring according to functionally responsive to positive controls PHA or
CEF  I. Samples that failed to meet the CEF I or PHA cut-off deﬁnition (i.e. “No”) were excluded from subsequent statistical analyses. Group IFN- response rates to PA peptide
pool  and/or rPA: 1For each Scharp or Empirical fraction, the numerator denotes number of subjects with positive IFN- responses to PAp and/or rPA; denominator denotes
number of subjects with complete days 0 and 21 PBMC samples that met  the CEF I (≥15 SFC) and PHA (≥200 SFC) cut-off criteria. 2Empirical deﬁnition of positive response
set  at a minimum of 9 SFC in wells with PAp or rPA and at least two-fold higher than background (SFC counts in wells with medium alone). Scharp analyses to deﬁne positive
responses was carried out at link http://www.scharp.org/zoe/runDFR/. Three subjects were excluded from ﬁnal analyses due to insufﬁcient cells for testing of either day 0
or  day 21 samples. §p = 0.06 (responder rate from empirical analyses) and †p = 0.04 (responder rate from Scharp analyses) for AV7909 (with 0.25 mg CPG 7909; groups 3 and
5)  compared to AVA alone, by Suissa-Shuster Exact test. (B) Individual subjects’ Day 21 (7 days after second immunization) IFN- ELISpot SFC counts following stimulation
with  rPA (B1) or PAp (B2). IFN- SFC counts per 3 × 105 PBMC are shown in each Arm for those samples that met  the cut-off criteria (i.e., those subjects included in the last
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mow  of Fig. 4A as Responders (empirical) that had greater than 9 SFC (dotted line))
but  not PAp SFC) was  identiﬁed for AV7909 (formulation 2) relative to AVA.
ontaining half (formulations 3 and 4) compared to full (formula-
ions 1 and 2) dose AVA were not statistically different (p = 0.57).
ig. 4B summarizes the IFN- T cell SFC cell count responses to PAp
nd/or rPA for each treatment group. ANOVA Statistics performed
n the SFC counts in response to rPA (i.e. not on responder rate)
emonstrated AV7909 F2 to be signiﬁcantly different from AVA;
his was not observed for the PAp mixture, however (Fig. 4B). The
 cell IFN- response (reported as SFC) at Day 21 did not correlate
ith any of the other endpoints (Fig. 3B).
.3. Anti-PA ELISA at Day 28
Of the investigated time points of Days 28, 42, and 70, IgG
nti-PA content was highest in recipients of AV7909 compared
o AVA, peaking at Day 28 (Fig. 5). IgG anti-PA content of 99
uman serum samples obtained 14 days following the second
mmunization (study day 28) ranged from 21 to 160 g/mL; this
as a 5-fold or higher mean response for recipients of AV7909
ompared to AVA. As expected, there was also an increase in
ean serum content within AVA recipients (average 21 g/mLatistical difference (p < 0.05 following post hoc analysis using ANOVA) for rPA SFC
on Day 28), compared to the saline (placebo) group. Signiﬁcant
correlations occurred between this parameter and the changes
in both ALC and CRP (Fig. 3B). There was no clear relationship
between humoral anti-PA IgG responses (or TNA peak NF50) and
cellular (ELISpot) SFC responses (both at r = 0.2, Fig. 3B).
4. Discussion
The main objective of this study was  to evaluate effects
of CPG 7909 as a vaccine component upon acute phase
cytokines/chemokines, changes in lymphocytic trafﬁcking (ALC),
CRP, as well as later cellular immune responses; and their cor-
relation with subsequent humoral immunity. In agreement with
previous reports of SC administration of CPG 7909 [2,18,19] we
found comparable response kinetics and magnitudes of IP-10 and
IL-6 serum content after the vaccines were administered IM.  These
responses were transient and returned to baseline by day 7, indi-
cating the potential to monitor repeated doses of CpG-adjuvanted
vaccines for potentially unregulated activation of innate immu-
nity by evaluating cytokine/chemokines or readily available CRP or
J.T. Minang et al. / Vaccine 32 (2014) 6847–6854 6853
0 20 40 60 80
0.1
1
10
100
1000 A rm 1 A V A A rm 2 A V 7 9 0 9 , F 1 A rm 3 A V 7 9 0 9 , F 2
A rm 4 A V 7 9 0 9 , F 3 A rm 5 A V 7 9 0 9 , F 4 A rm 6 , S a l in e
Study Day of Serum Collection
H
u
m
a
n
 I
g
G
 a
n
ti
-P
A
 (
µ
g
/m
L
)
Fig. 5. Serum content (g/mL) of IgG anti-PA from samples (n = 96–99) of vaccinated humans evaluated at Study Days 0, 28, 42 and 70. Each symbol represents mean (and
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1rder  to reach internally consistent precision (<30% CV for multiple tests of the ind
LC. These biomarkers were predictive of later adaptive immune
esponses, when measured at 24–48 h after vaccine administration,
n that they correlated with both later anti-PA levels (Day 28) and
eak TNA NF50 titers.
Anthrax vaccines are designed to provide protection by stimu-
ating the immune system to produce neutralizing antibodies that
ossess speciﬁcity for anthrax toxins. Anthrax toxins consist of the
3 kDa PA in combination with the 90 kDa lethal factor (LF) and/or
he 89 kDa edema factor (EF). PA is the principal target for vaccine
evelopment. The result of PA-induced IFN- production in PBMC
btained from AVA- and AV7909-vaccinated individuals indicates
h1 cellular immunity directed to PA after immunization. In addi-
ion to protection mediated by neutralizing antibodies, cellular
mmunity to PA may  provide rapid development of protective anti-
odies upon subsequent exposure. The increased cellular immunity
fter administration of formulations using 0.25 mg  of CPG 7909
bserved in this pilot study is of unveriﬁed clinical signiﬁcance at
resent.
In addition to the elicited T cell recall responses in some sub-
ects 7 days after the second administration of vaccine, AV7909
ormulations elicited anti-PA antibody levels (Fig. 5) as well as neu-
ralizing antibodies [14] that peaked by 14 or 21 days after the
econd vaccination (Day 28 or 35). On a subject by subject basis,
owever, T cell recall IFN- responses did not correlate with peak
ntibody responses to PA. In this respect, T cell responder rates
n study day 21 were not different between AV7909 recipients
hat received full and half dose AVA (regardless of the amount of
PG 7909) but peak TNA responses were lower for AV7909 groups
eceiving the lower dose of AVA (regardless of the amount of CPG
909) [14]. Furthermore, and surprisingly, the T cell responder
ates on study day 21 were statistically higher for the groups that
eceived lower amounts of CPG 7909. Peak TNA responses were
ot statistically different between those groups [14], however. This
 cell response was identiﬁed by quantitation of IFN--producing
ells rather than a marker of a Th2-type T cell response, such as
nterleukin-4. Killing of B. anthracis by murine macrophages [20]
nd human NK cells [21] involve IFN-; although IFN- production
y NK cells may  be down-regulated somewhat by anthrax lethal
oxin [21]. In mice, IFN--inducible chemokines CXCL9, -10 and -
1, contributed directly to in vitro anti-microbial effects against B.l samples).
anthracis Sterne strain spores [22], and IFN- was  produced by NK
cells in response to B. anthracis spores [23].
Human peak TNA response occurs at different time points for
different individuals [1], but typically between 28 and 35 days after
the ﬁrst dose in the series. The timeframe of peak circulation of T
cells is not known. It is clear that sampling only at one time point
(7 days after the second dose) provides an indication of the poten-
tial of two  doses of AV7909 to induce T cell responses, but does
not fully capture the differential kinetics of in vivo T cell activation,
migration to lymphoid organs and recirculation in peripheral blood.
Hence, because sampling the blood compartment only detects T
cells in transit, these data are biased by sampling one time point.
However, studies of T cell responses with Melan-A peptide vac-
cine adjuvanted with 0.5 mg  of CpG demonstrated circulating levels
of Melan-A speciﬁc T cells peaked at 7 days (4/7 subjects) and 10
days (3/7 subjects) after second immunization, and decline to near
baseline by day 14 [24], suggesting that our PBMC samples were
obtained within an appropriate window for sampling. Nonetheless,
the use of a single post-immunization sampling point may explain
some inter-group variability in this small study population.
Of note is the observation that of subjects that had positive
ELISpot responses, half responded to both rPA and PAp, revealing
an overlap in processed epitopes and predicted peptides (PAp). This
overlap in responses of rPA compared to the pool of PAp suggests
predicted peptides to be a suitable strategy for ELISpot testing in
unknown HLA populations with limited PBMC samples.
In summary (1) immunization with two  doses (14 days apart)
of an anthrax vaccine candidate consisting of AVA plus CPG 7909
was sufﬁcient to induce IFN--positive T cell recall responses in ex
vivo-stimulated PBMC collected 21 days following the ﬁrst immu-
nization; (2) in this pilot study, a dose (0.25 mg)  of CPG 7909,
lower than used in other vaccines in development, was adequate
to increase innate and adaptive immune responses beyond that
elicited by AVA (BioThrax) alone; (3) rPA and predicted peptides of
PA may  be adequate as recall antigens in assessing anthrax vaccine-
induced T cell recall responses of frozen PBMC; ﬁnally, (4) the innate
responses to CpG, such as decreased ALC and increased CRP, explain
a contribution of roughly 60% to the later peak anti-PA antibody
titer (Fig. 3B); the remaining variability is attributed to Subject
differences in response to PA antigen, perhaps HLA-related.
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